New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: A systematic literature review

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Brunasso, Alexandra Maria Giovanna ^a   Aberer, Werner ^a   Massone, Cesare ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; CROHN DISEASE; DERMATOMYOSITIS; HUMAN; INTERSTITIAL LUNG DISEASE; POLYMYOSITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; LUNG DISEASES, INTERSTITIAL; PATHOLOGY; RHEUMATIC FEVER;

ANTIBODIES, ANTINUCLEAR; DERMATOMYOSITIS; HUMANS; LUNG DISEASES, INTERSTITIAL; POLYMYOSITIS; RHEUMATIC FEVER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896890887     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/179180     Document Type: Review

References (62)

1. Bendewald M. J., Wetter D. A., Li X., Davis M. D. P., Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Archives of Dermatology 2010 146 1 26 30 2-s2.0-74549150155 10.1001/archdermatol.2009.328
2. Martin N., Li C. K., Wedderburn L. R., Juvenile dermatomyositis: new insights and new treatment strategies. Therapeutic Advances in Musculoskeletal Disease 2012 4 1 41 50 2-s2.0-84857486835 10.1177/1759720X11424460
3. Pachman L. M., Fedczyna T. O., Lechman T. S., Lutz J., Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Current Rheumatology Reports 2001 3 5 379 386 2-s2.0-0035487205
4. De Paepe B., Creus K. K., De Bleecker J. L., The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clinical and Developmental Immunology 2012 2012 10 2-s2.0-84855182041 10.1155/2012/369432 369432
5. Chinoy H., Salway F., John S., Fertig N., Tait B. D., Oddis C. V., Ollier W. E. R., Cooper R. G., Tumour necrosis factor- α single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 2007 46 9 1411 1416 2-s2.0-34548242316 10.1093/rheumatology/kem145
6. Lutz J., Huwiler K. G., Fedczyna T., Lechman T. S., Crawford S., Kinsella T. R., Pachman L. M., Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF α -308A allele in children with juvenile dermatomyositis. Clinical Immunology 2002 103 3 260 263 2-s2.0-0036085651 10.1006/clim.2001.5212
7. Cappelletti C., Baggi F., Zolezzi F., Biancolini D., Beretta O., Severa M., Coccia E. M., Confalonieri P., Morandi L., Mora M., Mantegazza R., Bernasconi P., Type i interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011 76 24 2079 2088 2-s2.0-79959630428 10.1212/WNL.0b013e31821f440a
8. Walsh R. J., Sek W. K., Yao Y., Jallal B., Kiener P. A., Pinkus J. L., Beggs A. H., Amato A. A., Greenberg S. A., Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis and Rheumatism 2007 56 11 3784 3792 2-s2.0-34948900717 10.1002/art.22928
9. Eloranta M.-L., Helmers S. B., Ulfgren A.-K., Rönnblom L., Alm G. V., Lundberg I. E., A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis and Rheumatism 2007 56 9 3112 3124 2-s2.0-34848898509 10.1002/art.22860
10. Gordon P. A., Winer J. B., Hoogendijk J. E., Choy E. H., Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews 2012 15 8
11. Amato A., A randomized, pilot trial of etanercept in dermatomyositis. Annals of Neurology 2011 70 3 427 436 2-s2.0-80052596202 10.1002/ana.22477
12. Brunasso A. M. G., Fancelli L., Massone C., Etanercept as steroid-sparing agent in dermatomyositis. Annals of Neurology 2011 70 4 670 671 2-s2.0-84855408657 10.1002/ana.22624
13. Martin N., Wedderburn L. R., Pilkington C. A., Davidson J. E., A survey of current practice in the management of Juvenile Dermatomyositis in the UK and Ireland. Clinical and Experimental Rheumatology 2011 29, supplement abstract from the 17th Paediatric Rheumatology European Society Congress 372
14. Musial J., Undas A., Celińska-Lowenhoff M., Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003 42 12 1566 1568 2-s2.0-0345099472 10.1093/rheumatology/keg388
15. Flendrie M., Creemers M. C. W., Welsing P. M. J., Den Broeder A. A., Van Riel P. L. C. M., Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Annals of the Rheumatic Diseases 2003 62 2 30 33 2-s2.0-0142218539
16. Flendrie M., Vissers W. H. P. M., Creemers M. C. W., de Jong E. M. G. J., van de Kerkhof P. C. M., van Riel P. L. C. M., Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Research & Therapy 2005 7 3 R666 R676 2-s2.0-24944532440
17. Urata Y., Wakai Y., Kowatari K., Nitobe T., Mizushima Y., Polymyositis associated with infliximab treatment for rheumatoid arthritis. Modern Rheumatology 2006 16 6 410 411 2-s2.0-33845529283 10.1007/s10165-006-0523-1
18. Hall H. A., Zimmermann B., Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis and Rheumatism 2006 55 6 982 984 2-s2.0-33846933775 10.1002/art.22358
19. Liozon E., Ouattara B., Loustaud-Ratti V., Vidal E., Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scandinavian Journal of Rheumatology 2007 36 6 484 486 2-s2.0-37349080150 10.1080/03009740701281293
20. Kiltz U., Fendler C., Braun J., Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy-three examples. Journal of Rheumatology 2008 35 10 2074 2076 2-s2.0-54949120577
21. Ramos-Casals M., Brito-Zerón P., Soto M.-J., Cuadrado M.-J., Khamashta M. A., Autoimmune diseases induced by TNF-targeted therapies. Best Practice and Research 2008 22 5 847 861 2-s2.0-56349156989 10.1016/j.berh.2008. 09.008
22. Brunasso A. G., Lo Scocco G., Massone C., Dermatomyositis during adalimumab therapy for rheumatoid arthritis. Journal of Rheumatology 2010 37 7 1549 1550 2-s2.0-77954450420 10.3899/jrheum.091413
23. Klein R., Rosenbach M., Kim E. J., Kim B., Werth V. P., Dunham J., Tumor necrosis factor inhibitor-associated dermatomyositis. Archives of Dermatology 2010 146 7 780 784 2-s2.0-77954820062 10.1001/archdermatol.2010.142
24. Ishikawa Y., Yukawa N., Kawabata D., Ohmura K., Fujii T., Usui T., Mimori T., A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clinical Rheumatology 2011 30 3 429 432 2-s2.0-79954627688 10.1007/s10067-010-1666-1
25. Riolo G., Towheed T. E., Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. Journal of Rheumatology 2012 39 1 192 194 2-s2.0-84855397150
26. Brunasso A. M. G., Puntoni M., Salvini C., Delfino C., Curcic P., Gulia A., Massone C., Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Dermato-Venereologica 2011 91 1 44 49 2-s2.0-78751496653 10.2340/00015555-0959
27. Nagashima T., Sato H., Minota S., Destructive arthropathy associated with dermatomyositis sine myositis positive for anti-Jo-1 and anti-cyclic citrullinated peptide antibodies. Journal of Rheumatology 2009 36 9 2133 2134 2-s2.0-70349245571 10.3899/jrheum.090183
28. Martínez-Cordero E., León D. E., Ortega L. A., Association of polymyositis with rheumatoid arthritis. Rheumatology International 2001 20 3 119 123
29. Brunasso A. M. G., Massone C., Is dermatomyositis in patients with rheumatoid arthritis induced by anti-TNF- α therapy? Clinical Rheumatology 2011 30 3 439 440 2-s2.0-79954608019 10.1007/s10067-010-1661-6
30. Nakajima A., Yoshino K., Soejima M., Kawaguchi Y., Satoh T., Kuwana M., Yamanaka H., High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatology International 2012 32 7 2057 2061 2-s2.0-79953716563 10.1007/s00296-011-1931-x
31. Edwards I. R., Aronson J. K., Adverse drug reactions: definitions, diagnosis, and management. The Lancet 2000 356 9237 1255 1259 2-s2.0-0034619028
32. Nebeker J. R., Barach P., Samore M. H., Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004 140 10 795 801 2-s2.0-2442433545
33. Ginn L. R., Lin J. P., Plotz P. H., Bale S. J., Wilder R. L., Mbauya A., Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis & Rheumatism 1998 41 400 405
34. Tincani A., Andreoli L., Bazzani C., Bosiso D., Sozzani S., Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmunity Reviews 2007 7 1 1 7 2-s2.0-35448943946 10.1016/j.autrev.2007.03.001
35. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., Boucquillard E., Siame J. L., Mariette X., Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Research & Therapy 2005 7 3 R545 R551 2-s2.0-21744446004
36. Solomon J., Swigris J. J., Brown K. K., Myositis-related interstitial lung disease and antisynthetase syndrome. Jornal Brasileiro de Pneumologia 2011 37 1 100 109 2-s2.0-79952660503 10.1590/S1806-37132011000100015
37. Marie I., Josse S., Decaux O., Dominique S., Diot E., Landron C., Roblot P., Jouneau S., Hatron P. Y., Tiev K. P., Vittecoq O., Noel D., Mouthon L., Menard J.-F., Jouen F., Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmunity Reviews 2012 11 10 739 745 2-s2.0-84857020171 10.1016/j.autrev.2012.01.006
38. Labirua-Iturburu A., Selva-O'Callaghan A., Vincze M., Dankó K., Vencovsky J., Fisher B., Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine 2012 91 4 206 211
39. Mumm G. E., McKown K. M., Bell C. L., Antisynthetase syndrome presenting as rheumatoid-like polyarthritis. Journal of Clinical Rheumatology 2010 16 7 307 312 2-s2.0-78049277570 10.1097/RHU.0b013e3181f3bf9c
40. Nagashima T., Iwamoto M., Minota S., Antisynthetase syndrome associated with long-standing rheumatoid arthritis. Rheumatology International 2011 31 5 705 706 2-s2.0-79955725092 10.1007/s00296-010-1467-5
41. Park C.-K., Kim T.-J., Cho Y.-N., Kim I.-S., Lee H.-J., Lee K.-E., Park S.-C., Kim J.-S., Park D.-J., Lee S.-J., Seo S.-R., Kim J.-C., Song S.-G., Lee S.-S., Park Y.-W., Development of antisynthetase syndrome in a patient with rheumatoid arthritis. Rheumatology International 2011 31 4 529 532 2-s2.0-79954449977 10.1007/s00296-009-1222-y
42. Cavagna L., Fusetti C., Montecucco C., Caporali R., Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. Journal of Rheumatology 2010 37 9 1967 2-s2.0-77956492558 10.3899/jrheum.091402
43. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., Pego-Reigosa J. M., Retamozo S., Bove A., Brito-Zeron P., Bosch X., Ramos-Casals M., Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Seminars in Arthritis and Rheumatism 2011 41 2 256 264 2-s2.0-80051801842 10.1016/j.semarthrit.2010.11.002
44. Hadjinicolaou A. V., Nisar M. K., Bhagat S., Parfrey H., Chilvers E. R., Östör A. J. K., Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology 2011 50 12 2297 2305 2-s2.0-82355170761 10.1093/rheumatology/ker289
45. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C. P., Einarsdottir H., Barbasso Helmers S., Elvin K., Crow M. K., Nennesmo I., Lundberg I. E., A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Annals of the Rheumatic Diseases 2008 67 12 1670 1677 2-s2.0-54549124536 10.1136/ard.2007. 077974
46. Iannone F., Scioscia C., Falappone P. C. F., Covelli M., Lapadula G., Use of etanercept in the treatment of dermatomyositis: a case series. Journal of Rheumatology 2006 33 9 1802 1804 2-s2.0-33748582304
47. Roddy E., Courtney P. A., Morris A., Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology 2002 41 10 1194 1195 2-s2.0-0036796754
48. Efthimiou P., Schwartzman S., Kagen L. J., Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Annals of the Rheumatic Diseases 2006 65 9 1233 1236 2-s2.0-33747805325 10.1136/ard.2005.048744
49. Hengstman G. J. D., Van Den Hoogen F. H. J., Barrera P., Netea M. G., Pieterse A., Van De Putte L. B. A., Van Engelen B. G. M., Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. European Neurology 2003 50 1 10 15 2-s2.0-0038646387 10.1159/000070852
50. Selva-O'Callaghan A., Martínez-Costa X., Solans-Laque R., Mauri M., Capdevila J. A., Vilardell-Tarrés M., Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology 2004 43 9 1196 1197 2-s2.0-4544288867 10.1093/rheumatology/keh285
51. Uthman I. W., El-Sayad J., Refractory polymyositis responding to infliximab. Rheumatology 2004 43 9 1198 1199 2-s2.0-4544255892 10.1093/rheumatology/keh268
52. Korkmaz C., Temiz G., Çetinbas F., Büyükkidan B., Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology 2004 43 7 937 938 2-s2.0-3242886427 10.1093/rheumatology/keh226
53. Choi K.-H., Yoo W.-H., Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatology International 2009 29 4 463 466 2-s2.0-59449084087 10.1007/s00296-008-0695-4
54. Sprott H., Glatzel M., Mitchel B. A., Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF- α type II receptor and IgG1. Rheumatology 2004 43 4 524 526 2-s2.0-1842844290
55. Dold S., Justiniano M. E., Marquez J., Espinoza L. R., Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clinical Rheumatology 2007 26 7 1186 1188 2-s2.0-34249914757 10.1007/s10067-006-0325-z
56. Riley P., Mccann L. J., Maillard S. M., Woo P., Murray K. J., Pilkington C. A., Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008 47 6 877 880 2-s2.0-44849137161 10.1093/rheumatology/ken074
57. de Oliveira S. K. F., de Almeida R. G., Fonseca A. R., Rodrigues M. C. F., Sztajnbok F., Diniz C., Indications and adverse events with the use of anti-TNF-alpha agents in pediatric rheumatology: experience of a single center. Acta Reumatológica Portuguesa 2007 32 2 139 150 2-s2.0-34848926871
58. Kim N. N., Lio P. A., Morgan G. A., Jarvis J. N., Pachman L. M., Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Archives of Dermatology 2011 147 7 831 835 2-s2.0-79955505027 10.1001/archdermatol.2011.49
59. Park J.-K., Yoo H.-G., Ahn D.-S., Jeon H.-S., Yoo W.-H., Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatology International 2012 32 11 3587 3590 2-s2.0-81555231733 10.1007/s00296-011-2220-4
60. Brunasso A. M. G., Laimer M., Massone C., Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Dermato-Venereologica 2010 90 2 183 185 2-s2.0-77950276066 10.2340/00015555-0777
61. De Gannes G. C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., Shojania K., Martinka M., Dutz J. P., Psoriasis and pustular dermatitis triggered by TNF- α inhibitors in patients with rheumatologic conditions. Archives of Dermatology 2007 143 2 223 231 2-s2.0-33846974080 10.1001/archderm.143.2.223
62. Brunasso A. M. G., Massone C., Thrombocytopenia associated with the use of anti-tumor necrosis factor- α agents for psoriasis. Journal of the American Academy of Dermatology 2009 60 5 781 785 2-s2.0-64749084123 10.1016/j.jaad.2008.12.001